Drug Trial Radar · NCT05456828
A Study of ASKG712 in Patients With Neovascular Age-Related Macular Degeneration
Last checked: Nov 19, 2026Latest source record: Jun 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
56
Actual
Start
Feb 10, 2023
Primary completion
Nov 3, 2025
Study completion Nov 3, 2025
Sponsor
- Lead sponsor
- Visara, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Suzhou Aosaikang Biopharmaceutical Co., Ltd.; AskGene Pharma, Inc.
- First posted
- Jul 13, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 50 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the Phase 1/2a study is comprised of single ascending-dose component (Part 1), multiple ascending-dose component (Part 2) and multiple-dose extension component (Part 3) to evaluate the safety, tolerability, pharmacokinetics, and efficacy of ASKG712 in patients with neovascular age-related macular degeneration (nAMD).
Conditions
- Neovascular Age-related Macular Degeneration
Interventions
ASKG712Biological
ASKG712 is a recombinant anti-VEGF humanized monoclonal antibody and Ang-2 antagonist peptide fusion protein, which has high specificity for the binding of VEGF-A and Ang-2.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of ocular adverse events (AEs) of the study eyesTime frame: Part 1: 6 weeks; Part 2: 20 weeks; Part 3: up to 36 weeks
- Incidence of non-ocular adverse events (AEs)Time frame: Part 1: 6 weeks; Part 2: 20 weeks; Part 3: up to 36 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai General Hospital
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.